Answers are grounded in this paper and cite their sources.
Nanodelivery systems offer a promising approach to enhance therapeutic precision for atherosclerosis by enabling targeted delivery to plaques, though significant challenges in clinical translation remain.
Atherosclerosis (ATS) remains a leading cause of global morbidity and mortality, driven by complex interactions among chronic inflammation, oxidative stress, and lipid accumulation within arterial walls. Although conventional therapies, including lipid-lowering and anti-inflammatory agents, have demonstrated clinical efficacy, their therapeutic potential is often limited by systemic side effects, suboptimal bioavailability, and poor site specificity. In this context, nanodelivery systems have emerged as a transformative approach to enhance therapeutic precision by enabling targeted, controlled, and stimuli-responsive delivery of drugs and genetic materials directly to atherosclerotic plaques. Recent advances in nanomedicine have led to the development of multifunctional nanoparticles capable of responding to key pathological features of ATS, such as elevated reactive oxygen species levels, acidic microenvironments, and dysregulated enzymatic activity, thereby improving therapeutic efficacy while minimizing off-target effects. Furthermore, nanoparticle-based platforms have shown significant promise for delivering nucleic acids, including small interfering RNAs and microRNAs, thereby facilitating modulation of critical molecular pathways involved in plaque progression and stabilization. This review provides a comprehensive overview of recent progress in nanoparticle-mediated drug and gene delivery systems for ATS, with particular emphasis on targeting strategies, microenvironment-responsive nanocarriers, and emerging therapeutic platforms for ATS. In addition, current challenges related to toxicity, large-scale manufacturing, reproducibility, and clinical translation are critically discussed, highlighting the need for standardized protocols and rigorous safety evaluations to advance the clinical applicability of nanomedicine in ATS management.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) conducted a review in Atherosclerosis. Nanodelivery systems was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: